Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

NCT03381053 · clinicaltrials.gov ↗

UNKNOWN

Status

3000

Enrollment

OTHER

Sponsor class

Conditions

Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST

Interventions

DRUG: Imatinib 400mg

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]